Molecular Partners has been granted a patent for recombinant multi-specific proteins targeting CD3, CD33, CD123, and CD70 for cancer treatment, particularly acute myeloid leukemia. The patent covers nucleic acids, pharmaceutical compositions, and methods for diagnosing and treating diseases in mammals, including humans. GlobalData’s report on Molecular Partners gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Molecular Partners AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Molecular Partners, Peptide pharmacophores was a key innovation area identified from patents. Molecular Partners's grant share as of January 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.

Multi-specific protein for treating cancer by targeting different antigens

Source: United States Patent and Trademark Office (USPTO). Credit: Molecular Partners AG

A recently granted patent (Publication Number: US11834504B2) discloses a recombinant protein designed for cancer treatment. The protein comprises a first binding agent that targets a protein on immune cells and at least two binding agents that target different tumor-associated antigens. Specifically, the first binding agent is a designed ankyrin repeat domain with binding specificity for CD3, with the protein capable of binding to tumor cells with a lower dissociation constant compared to proteins with only one tumor-associated antigen binding agent.

Furthermore, the patent claims cover various aspects of the recombinant protein, including its ability to bind human CD3 effectively, the amino acid sequences involved, and the potential for treating cancer. The patent also extends to nucleic acids encoding the protein, pharmaceutical compositions containing the protein, and a method for treating cancer by administering the recombinant protein to patients in need. This innovative approach to targeting both immune cells and tumor cells simultaneously could pave the way for more effective cancer therapies in the future.

To know more about GlobalData’s detailed insights on Molecular Partners, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies